Ultrasound in cardiovascular risk prediction: don't forget the plaque!

Introduction

Ultrasound‐based cardiovascular risk stratification has almost come full circle. Since its early description by Pignoli et al,[1] carotid intima–media thickness (CIMT) measures have been correlated with all traditional risk factors and cardiovascular diseases (CVD)[2] and have begun to find use in clinical trials aimed at evaluating antiatherosclerotic therapy (as a surrogate marker). Despite recent analyses from studies such as the Atherosclerosis Risk in Communities (ARIC) study,[3-4] which demonstrated the value of ultrasound in coronary heart disease (CHD) risk prediction, other analyses such as a recent meta‐analysis[5-6] have suggested that the improvement offered by CIMT was small and unlikely to be of clinical importance. However, the meta‐analysis did not include plaque data and has resulted in some confusion related to the value of ultrasound‐based subclinical atherosclerosis estimation and its role in CVD risk stratification. The analysis of the Multi‐Ethnic Study of Atherosclerosis (MESA) by Polak et al,[7] presented in this issue of JAHA—Journal of the American Heart Association, along with other recent reports that have incorporated plaque information, such as from the Three‐City Study,[8] have confirmed the importance of using plaque assessment for ultrasound‐aided CVD risk assessment. The current analysis further adds to the literature by examining several plaque definitions and reporting on their association with and value in risk prediction. Overall, the study showed value in CHD prediction but not in stroke, which, we agree with the authors, was likely related to the small number of stroke events that have accumulated so far in MESA, given previous results from other studies such as the ARIC study.[9]

The “intima–media thickness (IMT) complex” includes both the intima and the media (predominantly smooth muscle); in states of health, approximately 97.5% of the IMT complex is made of the media, whereas in the presence of atherosclerotic disease, although the intimal contribution to the IMT complex is relatively higher, an estimated 80% of the IMT complex still is formed by the media.[10] Given that atherosclerosis is a subintimal process, the measurement of IMT is in a way a surrogate of a surrogate. Plaque on the other hand reflects focal increases in the thickness of the arterial wall and is more likely to represent definite areas of atherosclerosis rather than medial hypertrophy. Therefore, relative to IMT, plaque may have a stronger association with CHD events, as demonstrated in this study.

The importance of plaque has been shown in several studies. In the ARIC study,[3-4] we have shown that information about plaque presence in addition to CIMT added predictive value irrespective of the CIMT category (<25th percentile, 25th to 75th percentile, and >75th percentile) and that its value was greater in women. Similarly, the Framingham Offspring Study[11] suggested that information about plaque presence (defined as an IMT in the internal carotid artery >1.5 mm) was associated with improved prediction of CVD risk (Table), whereas investigators from the Three‐City Study[8] showed that plaque but not CIMT added to CVD risk prediction. The investigators in the Three‐City Study further showed that as the number of sites with plaque increased, so did the hazards for incident CVD events.[8] Finally, a meta‐analysis of 11 population‐based studies (54 336 subjects) suggested that plaque was more strongly associated with incident CHD when compared to CIMT.[12] On the other hand, results related to CIMT alone have been mixed. A recent prospective European study (the Carotid Intima‐Media Thickness [CIMT] and IMT‐Progression as Predictors of Vascular Events in a High Risk European Population [IMPROVE] study) suggested that CIMT adds to CHD risk prediction,[13] whereas other studies such as the Carotid Atherosclerosis Progression Study (CAPS)[5] and a meta‐analysis[14] (14 CIMT studies, 45 828 subjects) suggested limited value for CIMT in CHD risk prediction and the Rotterdam Study[15] showed mixed results in that CIMT added value in the cardiovascular risk stratification of older women, but not of older men. While limitations in each of these analyses merit consideration, overall, in general plaque information consistently seems to add to traditional risk factors in CHD risk prediction.

The analyses presented by Polak et al[7] in this issue of JAHA has long been awaited since MESA reported on CIMT compared with coronary calcium score and other measures of atherosclerosis without examining the benefit of information about plaque.[16] This analysis, along with the preponderance of evidence from other large epidemiological studies, affirm the class IIA indication given to ultrasound‐based CIMT/plaque detection in the CHD risk prediction guidelines published by the American College of Cardiology and American Heart Association.[17]

However, when considering the value of ultrasound as a tool for assessing atherosclerosis risk, one must be cognizant of the various advantages and disadvantages. One of the limitations of ultrasound is image quality, which depends highly on the sonographer‘s ability to provide a comprehensive scan using appropriate standardized angles, etc. Tests such as the coronary calcium score, on the other hand, are fairly automated and easy to perform. Patient body habitus can similarly have a greater impact on ultrasound images relative to other imaging modalities. Finally, since CIMT measures are exacting, small changes (which may occur with minor changes in the angle of imaging) can have an impact on the measured value and hence the interpretation of the test. The advantages of ultrasound scanning are several: there are no major side effects to the test (minimal heating of tissue is possible), scans can be done on portable devices, and the overall acquisition time is fast, which offers the possibility of higher throughput, lower cost, and relative safety.

One significant technological advance (since epidemiological studies such as ARIC and MESA were performed) that will likely further enhance the value of ultrasound is the advent of 3D ultrasound imaging, which will allow a more quantitative approach in assessing the burden of atherosclerosis. Several groups have described the value of being able to assess the number of plaques and the plaque areas in the ultrasound images of the carotids;[8,18] however, these techniques would be more effective if they were more quantitative and less labor intensive. The advent of 3D ultrasound may now offer a relatively easier method for quantifying atherosclerotic plaque. Given that the mere presence of plaque adds to CHD risk prediction, one may hypothesize that plaque volumes will be of great benefit to risk prediction. Existing data have already suggested that quantification with plaque scores (formulated on the basis of number of plaques) and plaque area show value (ie, more plaques are associated with worse outcomes).[7-8] The early studies of 3D ultrasound plaque volumes measured with commercially available scanners have been promising and have shown that plaque volumes are highly associated with coronary calcium scores[19] and, in a small study, had a good negative predictive value for CHD.[20]

The need to improve CVD risk stratification remains, since the majority of CVD events occur in patients classified in the “low” and “intermediate” risk groups. As newer therapies are identified, improved methods to identify higher risk will also be necessary. An accurate, cost effective, and safe method will clearly be desirable. The current study published in this issue of JAHA[7] along with other recent studies suggest that ultrasound‐based plaque estimation remains an attractive option for assessing atherosclerosis and its associated risk.

Table 1.

Epidemiological Studies Reporting on the Use of CIMT and Carotid Artery Plaque in the Prediction of CHD and CVD Risk

	ARIC[4]	CAPS[5]	Framingham Offspring[11]	MESA[7]
Patients, n	13 145	4904	2965	6562
Mean follow‐up, y	15.1	8.5	7.2	7.8
Events
MI, n	867	73	NR	NR
CHD deaths/deaths, n	159	72	NR	NR
Other CVD events, n	Silent MI: 98; revasc.: 688	AP or MI: 271	Stroke: 74; CHD: 152; PAD: 26; CHF: 45	Stroke: 139; incident CVD: 515
Ultrasound data
IMT segments	All (mean)	ICA, CCA, bifurcation	Max. ICA, mean CCA	Mean ICA, max. ICA
Plaque presence	Yes	Yes	Yes	Yes
AUC with CIMT/plaque measurements
AUC (TRF)	0.742	0.719	0.748	0.743
AUC (CIMT+TRF)	0.750	0.724	0.751	0.750
AUC	0.755*	0.722*	0.758*	—
AUC (plaque+TRF)	0.751	NR	0.762	0.750
NRI with CIMT/plaque measurements added to TRF
NRI, %	9.9*	NR	7.3*	5.0*
NRI (CCA), %	16.2	–1.4	0	NR
NRI (ICA), %	NR	1.6	7.6	7.0*/6.8*

CIMT indicates carotid intima–media thickness; CHD, coronary heart disease; CVD, cardiovascular disease; ARIC, Atherosclerosis Risk in Communities; CAPS, Carotid Atherosclerosis Progression Study; MESA, Multi‐Ethnic Study of Atherosclerosis; MI, myocardial infarction; NR, not reported; revasc., coronary revascularizations; AP, angina pectoris; PAD, peripheral arterial disease; CHF, congestive heart failure; ICA, internal carotid artery, CCA, common carotid artery; AUC, area under curve; TRF, traditional risk factors; NRI, net reclassification index.

CIMT+plaque+TRF.

ICA+TRF.

CIMT+plaque.

Plaque.

Mean of the maximum IMT measured in ICA (based on CHD events).

Maximum IMT measured in ICA (based on CHD events).